GSK - グラクソ・スミスクライン （）

Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells are given to a patient to help the body fight diseases, such as cancer. BURLINGAME, CALIFORNIA, UNITED STATES, May 4, 2023 /⁨EINPresswire.com⁩/ -- Adoptive Cell Therapy Market …

GSK and Eli Lilly vaccines are in the spotlight, Shell beats expectations with profit of nearly $10bn, and other news to start your day.

Older adults, including those with underlying medical conditions such as diabetes and chronic heart and lung disease, are at increased risk of severe RSV illness The post US FDA approves GSK’s Arexvy, world’s first RSV vaccine for older adults appeared first on Express Pharma .

US approves GSK’s Arexvy, the world’s first RSV vaccine for older adults

LONDON (dpa-AFX) - The U.S. Food and Drug Administration approved GSK Plc.''s (GSK.L, GSK) Arexvy, the world''s first respiratory syncytial virus or RSV vaccine for older adults.Arexvy is approved f…

Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more

The £45bn company that will be created from the demerger of GlaxoSmithKline’s (GSK) consumer products arm is in talks to hire a roster of investment bankers in one of the year’s most prestigious City pitches.

A Swiss scientist has been convicted on charges that he conspired with his sister to steal trade secrets from the drugmaker GlaxoSmithKline to benefit biopharmaceutical companies they established, including one the Chinese government financed.

GlaxoSmithKline (GSK) and SK bioscience submitted a biologics license application to the Korean Ministry of Food and Drug Safety ((KMFDS)) seeking approval of SKYCovione, following…

GlaxoSmithKline’s (GSK) COVID-19 vaccine candidate developed with SK bioscience has been submitted for regulatory approval in South Korea after positive positive Phase III clinical data, the British drugmaker said on Friday. GSK said that SK bioscience will also apply to the World Health Organization (WHO) for emergency use listing and seek authorisations at individual regulatory […]

Glaxosmithkline plc - ADR (GSK) shares closed 0.7% higher than its previous 52 week high, giving the company a market cap of $110B. The stock is currently up 26.8% year-to-date, up 28.6% over the past 12 months, and up 50.1% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 42.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -36.1% The company's stock price performance over the past 12 months lags the peer average by -26.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Glaxosmithkline plc - ADR (GSK) shares closed today at 0.7% below its 52 week high of $44.09, giving the company a market cap of $110B. The stock is currently up 25.8% year-to-date, up 28.1% over the past 12 months, and up 48.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 21.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.3% The company's stock price performance over the past 12 months lags the peer average by -20.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.4% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Glaxosmithkline plc - ADR (GSK) shares closed today at 0.7% below its 52 week high of $44.09, giving the company a market cap of $110B. The stock is currently up 25.8% year-to-date, up 28.1% over the past 12 months, and up 48.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 20.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.3% The company's stock price performance over the past 12 months lags the peer average by -20.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.4% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Glaxosmithkline plc - ADR (GSK) shares closed today at 0.7% below its 52 week high of $44.09, giving the company a market cap of $110B. The stock is currently up 25.8% year-to-date, up 27.8% over the past 12 months, and up 48.1% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 1.2%. Trading Activity Trading volume this week was 20.7% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -37.3% The company's stock price performance over the past 12 months lags the peer average by -16.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.4% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Buy Now According to the report analysis, Global Autoimmune Disorder Drug Delivery Device Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027 states that AbbVie Inc., Bayer AG, Novartis AG, Amgen Inc., Merck KGaA, F. Hoffmann- La Roche Ltd., Teva Pharmaceutical Industries Ltd., Biogen Inc., GlaxoSmithKline Plc, Johnson Read More » The post Global Autoimmune Disorder Drug Delivery Device Market Is Predicted To Propel Owing To Surging Adoption Of Advanced Drug Delivery Devices: Ken Research appeared first on Ken Research .